Danish drugmaker Lundbeck on Thursday, March 25, lost its fight against a 2013 EU antitrust fine imposed for deals with rivals to delay sales of generic copies of its antidepressant citalopram after Europe’s top court sided with EU enforcers, reported Reuters.
The case is one of several in the European Commission’s decade-long crackdown against pay-for-delay deals which it says hurt competition and hold back innovation.
The EU competition enforcer had imposed a combined fine of €146 million (US$172 million) on Lundbeck and five generic drugmakers for such deals, prompting the companies to challenge the ruling at the General Court which upheld the EU decision in 2016.
The drugmakers subsequently appealed to the Luxembourg-based Court of Justice of the European Union (CJEU) which on Thursday dismissed all six motions and agreed with the lower tribunal that such deals were aimed at blocking rivals.
“The agreements at issue, which allowed the market entry of manufacturers of generic medicines to be delayed and which were accompanied by payments made by Lundbeck which, by virtue of their size, induced the manufacturers of generic medicines not to continue their efforts to enter the market, belong to that category of practices which are particularly harmful to competition,” CJEU judges said.
The other five generic drugmakers fined by the EU – Merck KGaA, Generics (UK), Arrow Group, Sun Pharmaceutical Industries, Xellia Pharmaceuticals, and Alpharma – also lost their appeals.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI